Nektar Therapeutics NKTR Restructuring Costs And Asset Impairment Charges
Restructuring Costs And Asset Impairment Charges at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCostsAndAssetImpairmentCharges.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's restructuring costs and asset impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's restructuring costs and asset impairment charges?
- Nektar Therapeutics (NKTR) reported restructuring costs and asset impairment charges of $796K in Q1 2026.
- How has Nektar Therapeutics's restructuring costs and asset impairment charges changed year-over-year?
- Nektar Therapeutics's restructuring costs and asset impairment charges increased by 371.0% year-over-year, from $169K to $796K.
- What does restructuring costs and asset impairment charges mean?
- This metric represents non-recurring expenses incurred from organizational restructuring initiatives and the write-down of asset values. It reflects management's efforts to streamline operations or adjust to changing business conditions by disposing of assets or reducing workforce. Investors monitor this to distinguish between core operational performance and one-time charges that impact profitability.